Stevens-Johnson syndrome after treatment with STI571: A case report

Liang Tsai Hsiao, Hung Ming Chung, Jen Tsun Lin, Tzeon Jye Chiou, Jin Hwang Liu, Frank S. Fan, Wei Shu Wang, Chueh Chuan Yen, Po Min Chen

Research output: Contribution to journalArticlepeer-review

109 Citations (Scopus)


Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life- threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.

Original languageEnglish
Pages (from-to)620-622
Number of pages3
JournalBritish Journal of Haematology
Issue number3
Publication statusPublished - 2002
Externally publishedYes


  • Chronic myeloid leukaemia
  • Skin
  • Stevens-Johnson syndrome
  • STI571
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Stevens-Johnson syndrome after treatment with STI571: A case report'. Together they form a unique fingerprint.

Cite this